Business
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdown Marlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdown\nMarlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, has been granted a skin care patent in South Korea.\nThe patent, METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING MMP1, covers the INTASYL RXI-185 compound that treats aging and skin disorders, including photo-aging. RXI-185 is a potent silencer of MMP1 expression in the skin, interrupting ultraviolet radiation (UVR) induced collagen breakdown, thereby improving and/or slowing the progression for skin thickening, elasticity and wrinkles. This is an additional patent in a family of patents covering INTASYL compounds that target aging skin disorders.\nThe Phio patent portfolio now consists of 81 issued patents, 77 of which cover the INTASYL siRNA gene silencing technology. The portfolio includes patents and applications broadly covering both the composition and methods of use of INTASYL compounds targeting immune checkpoint, cellular differentiation, and metabolism targets for ex vivo cell-based cancer immunotherapies.\n\"Our patent portfolio for Phio's INTASYL siRNA technology is extensive and robust,\" said Robert Bitterman, CEO of Phio Pharmaceuticals. \"The addition of this recent patent for treatment of photo-aging complements our current initiative in treating skin cancer.\"\nAbout Phio Pharmaceuticals Corp.\nPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.\nFor additional information, visit the Company's website, www.phiopharma.com.\nForward Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified ...